Company profile

Matthew E. Monaghan
Incorporated in
Fiscal year end
IRS number

IVC stock data



6 May 20
3 Jul 20
31 Dec 20


Company financial data Financial data

Quarter (USD) Mar 20 Dec 19 Sep 19 Jun 19
Revenue 218.44M 232.91M 235.77M 235.86M
Net income 732K -18.68M -8.04M -12.72M
Diluted EPS 0.02 -0.56 -0.24 -0.38
Net profit margin 0.34% -8.02% -3.41% -5.39%
Operating income 9.45M -3.84M 2.42M -4.51M
Net change in cash 18.87M -4.98M -4.47M -2.42M
Cash on hand 98.93M 80.06M 85.04M 89.51M
Cost of revenue 155.45M 164.95M 168.19M 170.79M
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue 927.96M 972.35M 966.5M 1.05B
Net income -53.33M -43.92M -76.54M -42.86M
Diluted EPS -1.59 -1.33 -2.34 -1.32
Net profit margin -5.75% -4.52% -7.92% -4.09%
Operating income -10.41M -18.29M -40.16M -15.22M
Net change in cash -36.84M -59.62M 52.29M 64.18M
Cash on hand 80.06M 116.91M 176.53M 124.23M
Cost of revenue 665.9M 704.67M 697.25M 763.85M

Financial data from Invacare earnings reports

Date Owner Security Transaction Code $Price #Shares $Value #Remaining
15 May 20 Karol Darcie Common Shares Payment of exercise Dispose F 5.66 1,305 7.39K 24,546
15 May 20 LaPlaca Anthony Common Shares Payment of exercise Dispose F 5.66 2,512 14.22K 83,369
15 May 20 Leneghan Kathleen P. Common Shares Payment of exercise Dispose F 5.66 5,521 31.25K 108,990
15 May 20 Monaghan Matthew E. Common Shares Payment of exercise Dispose F 5.66 41,326 233.91K 871,343
13F holders
Current Prev Q Change
Total holders 145 154 -5.8%
Opened positions 21 21
Closed positions 30 19 +57.9%
Increased positions 41 47 -12.8%
Reduced positions 52 58 -10.3%
13F shares
Current Prev Q Change
Total value 380.26M 448.25M -15.2%
Total shares 37.46M 37.64M -0.5%
Total puts 31.9K 62.7K -49.1%
Total calls 137.4K 14.8K +828.4%
Total put/call ratio 0.2 4.2 -94.5%
Largest owners
Shares Value Change
BLK BlackRock 5.12M $38.06M -2.9%
Dimensional Fund Advisors 2.66M $19.74M -1.8%
Renaissance Technologies 2.35M $17.44M +15.9%
Vanguard 2.25M $16.74M -0.3%
Barrow Hanley Mewhinney & Strauss 2.1M $15.63M +2.0%
Elk Creek Partners 1.84M $13.7M -1.3%
Pura Vida Investments 1.61M $11.95M +20.1%
Royce & Associates 1.48M $10.96M -27.9%
Millennium Management 1.4M $10.4M -7.9%
STT State Street 1.25M $9.26M +4.7%
Largest transactions
Shares Bought/sold Change
Wellington Management 1.07M +896.84K +529.7%
Royce & Associates 1.48M -571.27K -27.9%
Granahan Investment Management 0 -552.41K EXIT
Russell Investments 986.01K +527.69K +115.1%
California Public Employees Retirement System 71.98K -443.67K -86.0%
D. E. Shaw & Co. 449.93K -388.89K -46.4%
JPM JPMorgan Chase & Co. 516.34K +387.67K +301.3%
Paradigm Capital Management 348.5K +348.5K NEW
Renaissance Technologies 2.35M +322K +15.9%
Nuveen Asset Management 425.24K +285.28K +203.8%

Financial report summary

  • If the company's business transformation efforts are ineffective, the company's strategic goals, business plans, financial performance or liquidity could be negatively impacted.
  • Any major disruption or failure of the company’s information technology systems, or its failure to successfully implement new technology effectively, could adversely affect the company’s business and operations.
  • As the company outsources functions, it becomes more dependent on the entities performing those functions. Disruptions or delays at the company’s third-party service providers could adversely impact its operations.
  • IT Governance, Project Management and Contract Management competencies are critical to the company’s success in driving its significant cost improvement and transformation projects to achieve consistent and sustainable profitable growth.
  • The company is dependent upon its processes and procedures to ensure essential operational functions can continue during events that disrupt normal operations.
  • The inability to attract and retain, or loss of the services of, the company's key management and personnel could adversely affect its ability to operate the company's business.
  • The company is subject to certain risks inherent in managing and operating businesses in many different foreign jurisdictions.
  • If the company's products are not included within an adequate number of customer formularies, or if pricing policies otherwise favor other products, the company's market share and gross margin could be negatively affected.
  • The industry in which the company operates is highly competitive and some of the company's competitors may have greater financial resources, a more effective market strategy or better strategic execution.
  • The consolidation of health care customers and the company's competitors could result in a loss of customers or in additional competitive pricing pressures.
  • The company's business strategy relies on certain assumptions concerning demographic trends that impact the market for its products. If these assumptions prove to be incorrect, demand for the company's products may be lower than expected.
  • The adoption of healthcare reform and other legislative developments in the U.S. may adversely affect the company's business, results of operations and/or financial condition.
  • Changes in government and other third-party payor reimbursement levels and practices have negatively impacted and could continue to negatively impact the company's revenues and profitability.
  • The company is subject to a consent decree of injunction ("consent decree") with the U.S. Food and Drug Administration (“FDA”), the effects of which have been, and continue to be, costly to the company and could result in continued adverse consequences to the company's business.
  • Any failure by the company to comply with medical device regulatory requirements or receive regulatory clearance or approval for the company's products or operations in the United States or abroad could adversely affect the company's business.
  • The impact of the United Kingdom ("UK") exiting the European Union (the "EU") known as "Brexit" may adversely affect the company's business, results of operations and/or financial condition.
  • Being in the health care industry, the company is subject to extensive government regulation, and if the company fails to comply with applicable health care laws or regulations, the company could suffer severe civil or criminal sanctions or may be required to make significant changes to the company's operations that could have a material adverse effect on the company's results of operations.
  • The terms of the company's debt facilities and financing arrangements may limit the company's flexibility in operating its business.
  • The company may not be able to repay or refinance the 2021 Notes, 2022 Notes or 2024 Notes, and the issuance of common shares upon conversion of the 2021, 2022 or 2024 Notes could cause dilution to the company's existing shareholders.
  • Decreased availability or increased costs of materials could increase the company's costs of producing its products.
  • The company's ability to manage an effective supply chain is a key success factor.
  • The company's success depends on the company's ability to design, manufacture, distribute and achieve market acceptance of new products with higher functionality and lower costs.
  • Lower cost imports could negatively impact the company's profitability.
  • The company may be adversely affected by legal actions or regulatory proceedings.
  • Product liability claims may harm the company's business, particularly if the number of claims increases significantly or the company's product liability insurance proves inadequate.
  • The company's products may be subject to recalls, which could be costly and harm the company's reputation and business.
  • The company's operating results and financial condition could be adversely affected if the company becomes involved in litigation regarding its patents or other intellectual property rights.
  • The company's research and development and manufacturing processes are subject to federal, state and local requirements.
  • If the company is unable to protect its intellectual property rights or resolve successfully claims of infringement brought against it, the company's product sales and business could be affected adversely.
  • The company's capital expenditures could be higher than anticipated.
  • The company has long-term capital leases on its significant facilities located in Elyria and North Ridgeville, Ohio and Sanford, Florida, with the same owner/landlord.
  • The company may be unable to make strategic acquisitions without obtaining amendments to its credit agreement.
  • The company's revenues and profits are subject to exchange rate and interest rate fluctuations that could adversely affect its results of operations or financial position.
  • Additional tax expense or additional tax exposures could affect the company's future profitability and cash flow.
  • The company's reported results may be adversely affected by increases in reserves for uncollectible accounts receivable.
  • The company maintains cash balances globally in various financial institutions.
  • The company may experience volatility in the market price of its common shares
Management Discussion
  • The company operates in two primary business segments: North America and Europe with each selling the company's primary product categories, which include: lifestyle, mobility and seating and respiratory therapy products. Sales in Asia Pacific are reported in All Other and include products similar to those sold in North America and Europe.
  • *Date format is quarter and year in each instance.
  • The table above provides net sales change as reported and as adjusted to exclude the impact of foreign exchange translation and divestitures (constant currency net sales). “Constant currency net sales" is a non-Generally Accepted Accounting Principles ("GAAP") financial measure, which is defined as net sales excluding the impact of foreign currency translation and divestitures. The current year's functional currency net sales are translated using the prior year's foreign exchange rates. These amounts are then compared to the prior year's sales to calculate the constant currency net sales change. For the divestiture impact, the company adjusted a portion of net sales as the Dynamic Controls business was divested as of March 7, 2020.
Content analysis ?
H.S. junior Bad
New words: accurately, advantage, Allied, amid, approach, aspect, attached, begun, bolster, cautionary, characterized, Chinese, Christchurch, clarifying, closure, compounded, curtailment, deferral, demonstration, deployed, disposal, disposition, disrupt, disrupted, disruption, distancing, drew, Dynamic, economy, entirety, environment, epidemic, Exhibit, experienced, experiencing, fight, floating, foregoing, German, highly, holder, hospital, infection, intraperiod, lieu, LiNX, locally, magnitude, mandatory, medium, modernization, Motion, NEO, ongoing, onsite, outbreak, output, oxygen, pandemic, payroll, permanently, platform, pool, preemptively, preserve, profile, project, proxy, purified, raw, rebound, recommended, recoverable, redeem, redeemed, redemption, reinvesting, relieve, rely, resolve, SAP, scope, sinking, society, software, spread, stage, strain, subsidiary, supplier, taxable, temporary, therapeutic, treat, unexercised, unknown, unlimited, upgrading, urgent, volatility, voluntarily, voluntary, widespread, worker, workplace, worsening
Removed: absence, Accelerate, accretive, acquirer, activism, administration, announce, attack, auditor, Bidding, Brexit, charter, CID, classification, clinical, CMS, complaint, conform, Consolidate, converting, culture, cybersecurity, cycle, denote, Department, desired, Develop, differentiated, DOJ, Drug, efficiency, effort, evolving, excellence, excessive, execution, expand, expenditure, faster, Food, functionality, growing, heightened, hostile, implementing, importance, incur, influenced, informed, instituted, investigation, Investigative, IPG, issuing, Justice, Launch, Lead, legislated, legislation, leveraged, light, merit, million, monetary, narrow, optional, overhead, package, pattern, prevent, producing, pronouncement, Qualitative, Quantitative, qui, realignment, reassessed, reclassification, recover, redesign, referendum, reiterated, request, restore, reviewing, seasonal, seasonally, sequential, shifted, stranded, strategic, takeover, talent, tam, title, transitional, transparency, trend, unabsorbed, vulnerability, yield